VivoSeq
Respiratory

Asthma

790

Pipeline Programs↗

161

Active Trials↗

164

Companies Involved↗

Asthma is a highly competitive landscape with 790 programs across 164 companies. The most active players are Innovent Biologics (Suzhou) Co. Ltd., Acorda Therapeutics, Medigreen Biotechnology Corp.. 143 therapies are approved with 182 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

70/100

Mech. Concentration

12/100

Completion Rate

87/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Phase 1A

Acorda Therapeutics

1 program

Phase 1M

Medigreen Biotechnology Corp.

1 program

Phase 1T

TFF Pharmaceuticals, Inc.

1 program

Phase 1A

Alexza Pharmaceuticals, Inc.

1 program

Phase 1A

Altair Therapeutics, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical90

Etoricoxib

Novartis

Dupilumab

Azienda U.S.L. 1 di Massa e Carrara

Aclidinium Bromide

AstraZeneca

Montelukast Sodium

AstraZeneca

Mepolizumab

Glaxo Dba Glaxosmithkline

Phase 191

Alprazolam

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Zavegepant

Pfizer

Mogamulizumab

Kyowa Kirin, Inc.

REGN88

Regeneron

Iloprost

BTG International Inc.

Phase 2284

Clopidogrel

Sanofi

Risankizumab

AbbVie

Curcumin

Merck & Co.

Golimumab

Johnson & Johnson

Triamcinolone Acetonide

Bausch Health Americas, Inc.

Phase 3182

Lebrikizumab

Eli Lilly

Guselkumab

Johnson & Johnson

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Infliximab

Organon and Co

Influenza Virus Vaccine

Sanofi

Approved143

Salmeterol

Glaxo Dba Glaxosmithkline

Montelukast

Organon and Co

Mannitol

B. Braun Medical Inc.

Indacaterol

Novartis

Formoterol

Viatris

Analysis

Modality Breakdown

95%

Small molecule

923 of 970 classified programs — the dominant modality here.

5%ALL OTHERSMonoclonal antibody323%Protein / enzyme5<1%Peptide5<1%Vaccine4<1%Cell therapy1<1%

Small molecule leads; the ring shows all 970 classified programs, each share of the total. Modality classified for 98% of 1,051 pipeline programs.

Analysis

Trial Status

1,549

clinical trials

Completed1,104 · 71%
Terminated114 · 7%
Unknown status111 · 7%
Recruiting86 · 6%
Withdrawn57 · 4%
Active, not recruiting37 · 2%
Other40 · 3%

Clinical Trials

Trial Activity

1549 trials

Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma
Recruiting·SShanghai Mabgeek Biotech.Co.Ltd·Phase 3·NCT06837922·504 enrolled
Study to Improve Deployment Related Asthma by Using L-Citrulline Supplementation
Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT05259904·75 enrolled
Escitalopram in Asthma Patients With Frequent Exacerbation
Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT06216535·105 enrolled
Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma
Recruiting·AAnhui Palo Alto Pharmaceuticals, Inc.·Phase 2·NCT07324707·30 enrolled
Viral Infection in Asthma (VIA) Study
Recruiting·UUniversity of Virginia·Phase 4·NCT04380038·60 enrolled
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Recruiting·Sanofi logoSanofi·Phase 4·NCT05097287·1,324 enrolled
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Recruiting·Amgen logoAmgen·Phase 1·NCT06637371·124 enrolled
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Asthma
Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT07015749·12 enrolled
A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma
Recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd logoGuangdong Hengrui Pharmaceutical Co., Ltd·Phase 3·NCT06653322·400 enrolled
Azithromycin for Critical Asthma - Pediatrics
Recruiting·JJohns Hopkins All Children's Hospital·Phase 2/3·NCT06223828·100 enrolled
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Recruiting·Pfizer logoPfizer·Phase 2·NCT06977581·252 enrolled
Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT06948396·300 enrolled
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
Recruiting·WWindward Bio·Phase 2·NCT07120503·136 enrolled
A Clinical Trial of Soluble Fiber for Asthma
Recruiting·PPhoenix Children's Hospital·Phase 2·NCT06372249·105 enrolled
Metabolomics in the Diagnosis and Treatment of Asthma in Children
Recruiting·II.M. Sechenov First Moscow State Medical University·N/A·NCT07280364·100 enrolled
Page 1 of 104

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)